Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KARMA – Ketamine adjunctive sedation and recovery after mechanical ventilation
2025-523149-80-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in respiratory failure comparing Ketamine adjunctive sedation with Placebo adjunctive sedation (2 arms). Primary endpoint: Days alive and spent at home at 60 days. Planned start Apr 2026; status: authorised.
02
Drugs
ketamine
03
Conditions
respiratory failure
Beyond the preview
Go deeper on 2025-523149-80-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523149-80-00.